AF Ablation With High Power Short Duration RF

Launched by CLINICA MEDITERRANEA · Mar 8, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new method for treating atrial fibrillation (AF), a condition where the heart beats irregularly. The researchers want to see if using high power short duration radiofrequency energy during a procedure called catheter ablation can safely and effectively isolate specific areas in the heart to help reduce AF episodes. The trial will involve at least 850 patients with either paroxysmal (occasional) or persistent AF, and participants will be monitored for 12 months to see how well the treatment works and if there are any complications.

To be eligible for the study, patients must have paroxysmal or persistent AF and be currently taking blood-thinning medication (oral anticoagulation). However, those who have previously had ablation for AF, have certain heart conditions, or are pregnant cannot participate. If you join the study, you will receive treatment and regular follow-up visits to track your progress. This trial aims to gather important information that could improve AF treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with paroxysmal/persistent AF who signed the informed consent
• • Patients on active oral anticoagulation
• Exclusion Criteria:
• • Previous ablation for AF
• • Patients with LVEF\<35%
• • Women potentially pregnant
• • Contraindications to X-ray exposure
• • Congenital heart disease or cardiac surgery within 1 month